Beckman Daniella 4

What Happened

• Daniella Beckman, Chief Financial Officer of Tango Therapeutics, sold a total of 10,317 shares in open-market transactions on Feb 3, 2026 for combined proceeds of about $126,530 (10,204 shares @ $12.26 = $125,073; 113 shares @ $12.90 = $1,457).
• The Form 4 also reports two acquisitions on Feb 2, 2026: 44,330 shares (award/acquisition) and 265,980 shares reported as a derivative award (RSUs). The derivative award represents restricted stock units that convert to common shares upon vesting.

Key Details

• Transaction dates: grants on Feb 2, 2026; sales on Feb 3, 2026; Form 4 filed Feb 4, 2026 (no late filing indicated).
• Sale prices/ranges: weighted averages shown $12.26 and $12.90; reported price ranges were $11.88–$12.875 and $12.88–$12.91 (see footnotes F3/F4).
• Proceeds from sales: ~ $126,530 total.
• Vesting/tax notes: Footnote F1/F2 — the 265,980 shares are RSUs that vest over multi-year schedules (see below); the sales were automatic “sell-to-cover” transactions to satisfy tax withholding on RSU vesting, not discretionary sales by the CFO.
• Shares owned after transaction: total post-transaction holdings are not specified in the filing.
• Additional note: Footnote F5 describes a standard four-year vesting schedule for option grants (if applicable), though no option exercise was reported here.

Context

• These sales were reported as sell-to-cover related to RSU taxation (routine, automatic) rather than opportunistic open-market dispositions. The RSUs vest over time (example schedule in F1: ~33% Feb 1, 2027; ~33% Feb 14, 2028; ~34% Feb 12, 2029), so the reported derivative award will convert to shares upon vesting subject to continuous service.